Phase II proof-of-concept study of ALS 2158 in combination with antivirals (all oral interferon-free regimens) in patients with hepatitis C.

Trial Profile

Phase II proof-of-concept study of ALS 2158 in combination with antivirals (all oral interferon-free regimens) in patients with hepatitis C.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2012

At a glance

  • Drugs ALS 2158; Antivirals
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 26 Sep 2012 Status changed from planning to discontinued prior to enrolment.
    • 22 Feb 2012 Trial initiation is planned for the second half of 2012, according to a Vertex Pharmaceuticals media release
    • 11 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top